Loading clinical trials...
Loading clinical trials...
DE-111 ophthalmic solution will be evaluated for superiority in comparison with Timolol ophthalmic solution 0.5%, in IOP(intraocular pressure ) -lowering effect in primary open-angle glaucoma or ocula...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Santen Pharmaceutical Co., Ltd.
NCT07217678 · Glaucoma, Open-Angle Glaucoma, and more
NCT07447011 · Primary Open Angle Glaucoma, Obstructive Sleep Apnea, and more
NCT07396441 · Juvenile Open Angle Glaucoma, Dry Eye Disease (DED), and more
NCT07390890 · Primary Open Angle Glaucoma, Ocular Hypertension
NCT07358650 · Primary Open Angle Glaucoma
Santen study sites
Osaka, Osaka
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions